Decima 50 mg Injection

Brand Name: Decima

Molecule: Decitabine

Strength: 50 mg

Quantity: Single dose vial

Form: Injection

Packaging Type: Vial

Manufacturer/Marketed By: Getwell Pharma

Country of Origin: India

Description

Introducing Decima 50mg Injection, a powerful treatment specifically formulated for individuals battling acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS). Each injection contains Decitabine (50mg), a proven medication that works to inhibit the growth of cancer cells, promoting healthier blood cell production. Decima 50mg Injection is not only effective for AML and MDS but may also be utilized for other medical conditions at your doctor's discretion. Experience the potential for improved health and well-being with Decima 50mg Injection, a vital ally in your fight against blood cancer. Consult your healthcare provider to see if this treatment is right for you.

Benefits

Improves production of healthy blood cells
Reduces dependence on blood transfusions
Slows progression of myelodysplastic syndromes
Helps restore normal gene function in bone marrow cells
Proven treatment option for high-risk MDS patients

Indications and Usage

Decima 50 mg Injection is indicated for the treatment of patients with:

Myelodysplastic Syndromes (MDS)
- Refractory anemia
- Refractory anemia with ringed sideroblasts
- Refractory anemia with excess blasts
- Refractory anemia with excess blasts in transformation
Chronic Myelomonocytic Leukemia (CMML)
Intermediate-2 and high-risk IPSS (International Prognostic Scoring System) groups
Previously treated and untreated, de novo and secondary MDS

Treatment should be initiated and supervised by an oncologist or hematologist

How it Works

Decitabine inhibits DNA methyltransferase, leading to DNA hypomethylation. This action restores normal control of cell growth and differentiation in abnormal bone marrow cells. In rapidly dividing cancer cells, it also causes cell death, while non-dividing cells are less affected

Dosage & Administration

Decima 50 mg Injection is administered intravenously by trained healthcare professionals only.

Two recommended regimens:

Regimen 1

15 mg/m² IV infusion over 3 hours
Every 8 hours for 3 days
Repeated every 6 weeks

Regimen 2

20 mg/m² IV infusion over 1 hour
Once daily for 5 days
Repeated every 4 weeks
Patients should receive at least 4 cycles
Dose adjustments may be required based on blood count recovery
Regular monitoring of CBC, platelets, liver and kidney function is mandatory

Side Effects

Common side effects:

Neutropenia
Thrombocytopenia
Anemia
Fatigue
Fever
Nausea
Diarrhea or constipation
Cough
Hyperglycemia

Serious side effects:

Severe infections
Febrile neutropenia
Severe bleeding
Liver function abnormalities
Pulmonary edema
Cardiac rhythm disturbances
Intracranial hemorrhage

Warning and Precaution

Causes severe neutropenia and thrombocytopenia
High risk of infections – early use of antibiotics or growth factors may be required
Not recommended during pregnancy – may cause fetal harm
Women should avoid pregnancy during treatment and for 1 month after
Men should avoid fathering a child during treatment and for 2 months after
Use caution in patients with liver or kidney impairment
Not to be used in uncontrolled infections
Cytotoxic drug – proper handling and disposal required